NCT01348438已完成不适用
Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial
Medtronic Cardiac Rhythm and Heart Failure18 个研究点 分布在 4 个国家目标入组 125 人开始时间: 2011年9月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 125
- 试验地点
- 18
- 主要终点
- All-cause mortality
研究概览
简要总结
The purpose of the study is to evaluate the safety and clinical performance of the Engager Transcatheter Aortic Valve Implantation System in patients with severe aortic valve stenosis who are at high risk for surgical valve replacement.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Severe aortic stenosis defined as one or more of the following by Doppler echocardiography: mean gradient > 40 mmHg; max velocity > 4m/s; aortic valve area ≤ 0.8 cm
- •Symptoms related to aortic valve disease, and NYHA Functional Class II or greater.
- •Logistic EuroSCORE predicted risk for mortality of ≥20%, or comorbidity judged by the investigator to pose an absolute or relative contraindication for conventional aortic valve replacement.
- •Patient is indicated for aortic valve implantation with a biological prosthesis (tissue valve) in accordance with the 2007 European Society of Cardiology (ESC) Guidelines for management of valvular heart disease.
- •Age ≥ 18 years.
- •Echocardiographically determined aortic annulus diameter of ≥19 mm and ≤ 26 mm in a long-axis view.
排除标准
- •Congenital unicuspid or bicuspid aortic valve.
- •Severe eccentricity of calcification, defined as calcium deposits larger than 6mm in diameter.
- •Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
- •Left ventricular ejection fraction < 25%, as determined by contrast ventriculography, or echocardiography or radionuclide angiography if contrast ventriculography not available
- •Hypertrophic obstructive cardiomyopathy.
- •Patients with life expectancy less than 12 months due to an underlying non-cardiac comorbid disease.
- •Known hypersensitivity or contraindication that cannot be adequately controlled with pre-medication to any study medication or material, such as contrast medium or Nitinol.
- •Sepsis or acute endocarditis.
- •Blood dyscrasia such as acute anemia, leucopenia, or thrombocytopenia; bleeding diathesis, or coagulopathy.
- •Renal insufficiency assessed by creatinine > 2.5 mg/dl and/or end stage renal disease requiring chronic dialysis.
- •Active peptic ulcer or GI bleeding within 3 months from the planned index procedure.
- •Untreated clinically significant coronary artery disease requiring revascularization.
- •Cardiogenic shock, suspected cardiogenic shock, or hemodynamic instability requiring inotropic support or mechanical heart assistance.
- •Significant aortic disease, including abdominal and thoracic aortic aneurysm, defined as maximal luminal diameter of 5 cm or greater.
- •Need for emergency surgery, cardiac or non-cardiac.
- •History of myocardial infarction in the last 6 weeks.
- •History of TIA or CVA in the last 6 months.
- •Therapeutic invasive cardiac procedure, with the exception of aortic balloon valvuloplasty, performed within 30 days of the planned date of valve implantation, or 6 months in the case of drug-eluting stents.
- •Pre-existing prosthetic heart valve or prosthetic ring in any position.
- •Mitral regurgitation greater than 2+ by angiography or moderate by echocardiography.
- •Patient refuses a blood transfusion.
- •Patient is currently enrolled in another investigational device or drug trial that may influence the outcome of this trial.
结局指标
主要结局
All-cause mortality
时间窗: 30 Days
All-cause mortality within 30 days post-implantation
次要结局
- Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) free survival at 30 days and 6 months post implantation(6 months)
- Device and procedure related Major Adverse Events(30 days)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
不适用
Engager Align Post-market Clinical StudyAortic Valve StenosisNCT02149654Medtronic Bakken Research Center27
进行中（未招募）
不适用
PrizValve® Transcatheter Aortic Valve Replacement StudyAortic Valve StenosisNCT04836897Shanghai NewMed Medical Co., Ltd.120
已完成
不适用
Engager Direct Aortic Clinical StudyAortic Valve StenosisNCT01789567Medtronic Cardiac Rhythm and Heart Failure20
终止
不适用
Evaluation of the Safety and Clinical Performance of the Connected Catheter StudyUrinary RetentionChronicNCT05330598Spinal Singularity26
已完成
不适用
Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Investigational Device Exemption CohortCongenital Heart DefectsDysfunctional Right Ventricular Outflow Tract ConduitsNCT00740870Medtronic Cardiovascular171